Welcome to our dedicated page for Galecto news (Ticker: GLTO), a resource for investors and traders seeking the latest updates and insights on Galecto stock.
Galecto Inc. (GLTO) is a clinical-stage biotechnology company pioneering small-molecule therapies for fibrosis and cancer. This page provides official updates on their innovative pipeline, including inhibitors targeting galectin-3 and LOXL2 proteins implicated in disease progression.
Investors and researchers will find timely announcements about clinical trials, regulatory milestones, and strategic collaborations. Key focus areas include updates on lead candidates like GB0139 for pulmonary fibrosis and GB1211 for oncology applications, alongside developments in combination therapies with immune checkpoint inhibitors.
All content is sourced directly from company releases to ensure accuracy. Bookmark this page to monitor progress across Galecto's therapeutic programs and stay informed about emerging data in precision medicine for fibrotic diseases and cancer.
BOSTON, April 13, 2023 – Galecto, a clinical-stage biotechnology company focusing on treatments for fibrosis and cancer, will present two posters at the American Association for Cancer Research (AACR) Annual Meeting from April 14-19 in Orlando, Florida.
The company is conducting a Phase 2a trial of GB1211, a galectin-3 inhibitor, combined with atezolizumab for treating non-small cell lung cancer (NSCLC). Presenting data suggests that inhibiting galectin-1 and dual inhibition of galectin-1 and galectin-3 could offer new cancer therapies.
During the meeting, the following abstracts will be presented:
- Abstract LB104: Preclinical evaluation of Galectin-1 inhibitor on April 17.
- Abstract LB173: Benefits of blocking both Galectin-1 and Galectin-3 on April 18.
Galecto, Inc. (NASDAQ: GLTO) reported its operating and financial results for the year ended December 31, 2022. The company completed the enrollment of the Phase 2b GALACTIC-1 trial for GB0139 in idiopathic pulmonary fibrosis and has three compounds in Phase 2 clinical trials with positive results reported in 2022. Financially, cash equivalents totaled approximately $66.1 million, providing a runway into the second half of 2024. However, the net loss for the year was $61.6 million, resulting in a loss per share of $(2.43), compared to $(2.05) in the previous year. The company anticipates significant milestones in 2023, including key trial results.
FAQ
What is the current stock price of Galecto (GLTO)?
What is the market cap of Galecto (GLTO)?
